CVS is set to drop Zepbound as a medicine, but will continue to carry other popular weight loss drugs instead.

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging.

Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the future.

Lilly recently revised its revenue forecast for 2024 after seeing weaker-than-expected growth for Zepbound and diabetes brand Mounjaro in the last three months of the year, although, they still ...